Biomarin Pharmaceutical Stock Story
| BMRN Stock | USD 91.51 0.71 0.77% |
About 56% of Biomarin Pharmaceutical's investor base is looking to short. The analysis of the overall investor sentiment regarding Biomarin Pharmaceutical suggests that many traders are alarmed. Biomarin Pharmaceutical's investor sentiment overview provides quick insight into current market opportunities from investing in Biomarin Pharmaceutical. The current market sentiment, together with Biomarin Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use Biomarin Pharmaceutical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Biomarin Pharmaceutical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Biomarin daily returns and investor perception about the current price of Biomarin Pharmaceutical as well as its diversification or hedging effects on your existing portfolios.
Biomarin |
Requested story not found. it has been either deleted or moved. View all stories for Biomarin Pharmaceutical.
Biomarin Pharmaceutical Latest Timeline
Biomarin Pharmaceutical is listed for 91.51. About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Biomarin Pharmaceutical was currently reported as 26.25. The company has Price/Earnings To Growth (PEG) ratio of 0.76. Biomarin Pharmaceutical had not issued any dividends in recent years.Check out Biomarin Pharmaceutical Hype Analysis, Biomarin Pharmaceutical Correlation and Biomarin Pharmaceutical Performance. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.